Optimal dosing of lasmiditan in the management of acute migraine attack: A systematic review and meta-analysis

Background: The current target of migraine treatment is focused on Triptans. Lasmiditan, a non-vasoconstrictive and highly selective 5HT1F receptor agonist is a novel therapeutic discovery for migraine for patients with cardiovascular (CV) risk factors or stable cardiovascular diseases and who fail...

Full description

Bibliographic Details
Main Authors: Roopa Satyanarayan Basutkar, Chris Elizabeth Vinod, Shruthi Jaya Saju, Bhavya Chebrolu, Sivasankaran Ponnusankar
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Annals of Indian Academy of Neurology
Subjects:
Online Access:http://www.annalsofian.org/article.asp?issn=0972-2327;year=2021;volume=24;issue=2;spage=155;epage=163;aulast=Basutkar